The Pharmaceutical industry on apis.io has 720 member providers. 533 of them, 74 percent, score in the minimal band. Only one is exemplar and three are strong. The more telling number concerns the companies that actually make drugs. Pfizer, Merck, Novartis, Roche, AstraZeneca, Eli Lilly, GSK, Sanofi, Bayer and AbbVie publish zero APIs between them on the catalog. Johnson & Johnson publishes one.
Membership here is computed from tags rather than from a fixed list. That is why the set mixes drug makers, pharmacies, e-prescribing networks, clinical data standards and the software companies that sell into all of them. The 720 rows hold 591 APIs, but only 187 of those count as published, which means they come from contracts the provider ships rather than ones we split or inferred.
Who carries the industry
| Provider | Kin Score | Band | APIs |
|---|---|---|---|
| Veeva | 76.1 | exemplar | 9 |
| DoseSpot | 58.3 | strong | 27 |
| Optum | 57.0 | strong | 163 |
| Truepill | 53.4 | developing | 30 |
| TraceLink | 49.6 | developing | 6 |
| Walgreens | 36.1 | thin | 3 |
| Pfizer | 1.5 | minimal | 0 |
Every provider at the top sells to pharma or sits in the dispensing chain. Veeva runs the content and data cloud that commercial, clinical, quality and regulatory teams work in. DoseSpot embeds Surescripts- and EPCS-certified e-prescribing in other vendors’ software. Optum runs one of the largest pharmacy networks in the United States, and with 163 APIs it is the largest surface in the set. TraceLink covers serialization and supply integrity. Truepill does API-driven fulfillment and dispensing. Walgreens is the only retail pharmacy with a real surface, and it is thin.
The drug makers score on their websites, not on APIs. Pfizer is at 1.5, Merck and Eli Lilly at 3.6, Novartis at 4.5. GSK, at 17.1, is the highest of the ten. J&J reaches 25.0 with a single API.
Why this is not simply a failing grade
This is a real pattern, not a gap in our crawl. A large drug maker’s integration surface is almost always private: partner portals, EDI with wholesalers, serialization exchanges run through vendors like TraceLink, and clinical data moved through CROs and platforms like Veeva. The rubric measures the public API surface only, so a company whose integrations all run through intermediaries scores like a company with none. The fair way to read it is that pharma has outsourced its public interface to its vendors.
That has a cost all the same. Drug makers do run patient programs, medical information requests, product labeling and adverse-event intake, all of which are public-facing, and agents now try to reach them. Today an agent that needs authoritative product information from a manufacturer finds nothing to call.
One record to watch
Veeva’s row reads 76.1. When we profiled it on 2026-10-04 it was 72.8, so it has moved up 3.3 since that post.
Takeaway
What would move the industry is a manufacturer publishing even one public contract: product and label data, or a medical information request intake with a documented OpenAPI. Any of the ten could take the first exemplar slot held by an actual drug maker. Until then, the vendors are the industry’s API.
See the full industry at apis.io/industries/pharmaceutical/.